1

1. Pfizer Inc. $1,624,023 257 payments
2. Eiger BioPharmaceuticals, Inc. $192,057 18 payments
3. Array BioPharma Inc. $9,671 1 payment
4. Biohaven Pharmaceutical Holding Company Ltd. $5,000 1 payment

1. A Phase 23 Randomized Doubleblind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $501,411 65 payments
2. A Phase 4 Openlabel Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention $363,478 17 payments
3. Phase 3 Multicenter Openlabel Study to Assess the Longterm Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $315,692 64 payments
4. Lmd-002 $138,075 8 payments
5. A Phase 4 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens $126,410 27 payments
6. Phase 3 Multicenter Randomized Doubleblind Group Sequential Placebocontrolled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $117,465 47 payments
7. Phase 12A Dose Escalation and Expansion Study Evaluating Safety Tolerability Pharmacokinetic Pharmacodynamics and Antitumor Activity of Pf06873600 As A Single Agent and in Combination With Endocrine Therapy $78,079 6 payments
8. A Longterm Openlabel Followup Study of Tofacitinib for Treatment of Juvenile Idiopathic Arthritis Jia $63,358 8 payments
9. A Phase 3 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents 6 to 18 Years of Age $54,681 22 payments
10. Lmd-001 $39,750 2 payments

1. Professional salary support $192,057 18 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.